Hernández NL, Álvarez CA, Gómez N, Castorena I, Pedroza MÁ, Huerta LJG

Idioma: Español
Referencias bibliográficas: 27
Paginas: 121-125
Archivo PDF: 55.20 Kb.

RESUMEN

Durante la administración repetida de cualquier droga, todos los pacientes son susceptibles a presentar reacciones de hipersensibilidad, ameritando con ello la suspensión del fármaco. Sin embargo existen casos especiales en los que es necesario continuar algunas drogas ante la falta de otras opciones de tratamiento, considerándose la desensibilización una opción para lograrlo. La hipersensibilidad a ciertos antineoplásicos llevó a la creación de nuevos fármacos con menor inmunogenicidad para evitarla, no obstante en aquellos países donde no están disponibles, los protocolos de desensibilización son sumamente importantes para completar el tratamiento de aquellos pacientes que han presentado una reacción mediada por anticuerpos. Se presenta el caso de un paciente pediátrico con leucemia linfoblástica aguda y reacción anafiláctica a L-asparaginasa que amerita la readministración del fármaco para completar inducción a la remisión en su segunda recaída.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Intern Med 1981; 94: 66-72

2. Vervolet D, Durham S. Adverse reactions to drugs. BMJ 1998; 316: 1511-1514.

3. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24(3): 253-62.

4. Rosi F, Incorvania C, Mauro M. Hypersensitivity reactions to chemotherapeutic antineoplastic agents. Recenti Prog Med 2004; 95(10): 476-81. Abstract.

5. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009; 102(3): 179-87; quiz 187-9, 222. Review.

6. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 1994; 53: 121-122

7. Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001; 24(10): 767-79.

8. Shanholtz C. Acute life-threatening toxicity of cancer treatment. Crit Care Clin 2001; 17(3): 483-502.

9. Fu CH, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother 2007; 8(12): 1977-84.

10. Zalewska-Szewczyk B, Andrzejewski W, Bodalski J. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2004; 43(5): 600-2.

11. Albertsen BK, Schrøder H, Jakobsen P, Avramis VI, Müller HJ, Schmiegelow K, Carlsen NT. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002; 38(5): 310-6.

12. Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, Kelly KM, Laverdière C, Michon B, Schorin M, Cohen HJ, Sallan SE, Silverman LB. Pediatr Blood Cancer. 2009 Aug 11. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. E print.

13. Soyer OU, Aytac S, Tuncer A, Cetin M, Yetgin S, Sekerel BE. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. J Allergy Clin Immunol 2009; 123(4): 895-9.

14. Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK, Wang B, Pui CH, Relling MV. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12(10): 1527-33.

15. Zalewska-Szewczyk B, Gach A, Wyka K, Bodalski J, MBynarski W. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med 2009; 9: 113-116.

16. Sikorska-Fic B, Makowska K, Rokicka-Milewska R. New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to L-asparaginase E. coli and erwinase. Wiad Lek 1998; 51 Suppl 4: 233-6. (Abstract).

17. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belison J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000; 18: 102-105.

18. Markman M, Hsieh F, Zannoti K, Webster K, Peterson G, Kulp B et al. Initial experience with novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin hypersensitivity reactions. J Cancer Resp Clin Oncol 2004; 130: 25-28.

19. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belison J. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 1999; 125: 427-429.

20. Castells M. Drug desensitization in oncology: Chemotherapy agents and monoclonal antibodies in Pichler WJ (ed) Drug Hypersensitivity. Basel Karger 2007: 413-425.

21. Sweet AU, Stieber DA. Successful etoposide desensitization protocol in autologous stem cell transplant. J Oncol Pharm Practice 2001; 7: 55-56.

22. Marín-Pozo JF, Carmona-Alvarez MT, Toledo-López A, Salas-García A, Oya Álvarez-de Morales B, Ramírez-Huertas JM. [Asparaginase desensitization in two patients with previous hypersensitivity]. Farm Hosp 2006; 30(2): 132-4.

23. Guo Y. [Desensitization therapy of acute lymphocytic leukemia with injection of L-asparaginase (Report of 5 cases)]. Zhonghua Er Ke Za Zhi 2005; 43(4): 309-10. Chinese.

24. Bonno M, Kawasaki H, Hori H, Umemoto M, Komada Y, Sakurai M. Rapid desensitization for L-asparaginase hypersensitivity. J Allergy Clin Immunol 1998; 101 (4 Pt 1): 571-2. PubMed PMID: 9564820.

25. Dao C, Zittoun R, Bousser J. [A technic for “desensitization” in case of asparaginase anaphylaxis during acute leukemia]. Nouv Presse Med 1973; 2(16): 1073. French.

26. Jaffe N, Traggis D, Das L, Moloney WC, Hann HW, Kim BS, Nair R. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res 1971; 31(7): 942-9.

27. Tallal L, Tan C, Oettgen H, Wollner N, McCarthy M, Helson L, Burchenal J, Karnofsky D, Murphy ML. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 1970; 25(2): 306-20.